Suberoylanilide hydroxamic acid (SAHA) inhibits EGF-induced cell transformation via reduction of cyclin D1 mRNA stability

Toxicology and Applied Pharmacology

Volumn 263, Issue 2, 2012, Pages 218-224

  Zhang, Jingjie ^a,b   Ouyang, Weiming ^b   Li, Jingxia ^b   Zhang, Dongyun ^b   Yu, Yonghui ^b   Wang, York ^b   Li, Xuejun ^a   Huang, Chuanshu ^b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell transformation; Cyclin D1 mRNA stability; SAHA

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR; HUR PROTEIN; LUCIFERASE; MESSENGER RNA; PROTEIN P21; VORINOSTAT;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL ANCHORAGE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; DOWN REGULATION; EPIDERMIS CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REPORTER GENE; RNA DEGRADATION; RNA STABILITY; TRANSCRIPTION REGULATION;

ANIMALS; CELLS, CULTURED; CYCLIN D1; DOWN-REGULATION; EPIDERMAL GROWTH FACTOR; G0 PHASE; G1 PHASE; HALF-LIFE; HU PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGENS; HYDROXAMIC ACIDS; MICE; RNA STABILITY; RNA, MESSENGER; TIME FACTORS;

EID: 84865103495     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.06.012     Document Type: Article

References (50)

1. Abdelmohsen K., Gorospe M. Posttranscriptional regulation of cancer traits by HuR. Wiley Interdiscip. Rev. RNA 2010, 1:214-229.
2. Aghib D.F., Bishop J.M., Ottolenghi S., Guerrasio A., Serra A., Saglio G. A 3' truncation of MYC caused by chromosomal translocation in a human T-cell leukemia increases mRNA stability. Oncogene 1990, 5:707-711.
3. Alao J.P., Stavropoulou A.V., Lam E.W., Coombes R.C., Vigushin D.M. Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells. Mol. Cancer 2006, 5:8.
4. Anderson S.N., Towne D.L., Burns D.J., Warrior U. A high-throughput soft agar assay for identification of anticancer compound. J. Biomol. Screen. 2007, 12:938-945.
5. Audic Y., Hartley R.S. Post-transcriptional regulation in cancer. Biol. Cell 2004, 96:479-498.
6. Bae D.S., Cho S.B., Kim Y.J., Whang J.D., Song S.Y., Park C.S., Kim D.S., Lee J.H. Aberrant expression of cyclin D1 is associated with poor prognosis in early stage cervical cancer of the uterus. Gynecol. Oncol. 2001, 81:341-347.
7. Barre B., Perkins N.D. A cell cycle regulatory network controlling NF-kappaB subunit activity and function. EMBO J. 2007, 26:4841-4855.
8. Benjamin D., Moroni C. mRNA stability and cancer: an emerging link?. Expert Opin. Biol. Ther. 2007, 7:1515-1529.
9. Bianchi A.B., Fischer S.M., Robles A.I., Rinchik E.M., Conti C.J. Overexpression of cyclin D1 in mouse skin carcinogenesis. Oncogene 1993, 8:1127-1133.
10. Biliran H., Wang Y., Banerjee S., Xu H., Heng H., Thakur A., Bollig A., Sarkar F.H., Liao J.D. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin. Cancer Res. 2005, 11:6075-6086.
11. Blancato J., Singh B., Liu A., Liao D.J., Dickson R.B. Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. Br. J. Cancer 2004, 90:1612-1619.
12. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006, 5:769-784.
13. Buckley M.F., Sweeney K.J., Hamilton J.A., Sini R.L., Manning D.L., Nicholson R.I., deFazio A., Watts C.K., Musgrove E.A., Sutherland R.L. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993, 8:2127-2133.
14. DiGiovanni J., Rho O., Xian W., Beltran L. Role of the epidermal growth factor receptor and transforming growth factor alpha in mouse skin carcinogenesis. Prog. Clin. Biol. Res. 1994, 387:113-138.
15. Ding J., Ning B., Gong W., Wen W., Wu K., Liang J., He G., Huang S., Sun W., Han T., Huang L., Cao G., Wu M., Xie W., Wang H. Cyclin D1 induction by benzo [a]pyrene-7,8-diol-9,10-epoxide via the phosphatidylinositol 3-kinase/Akt/MAPK- and p70s6k-dependent pathway promotes cell transformation and tumorigenesis. J. Biol. Chem. 2009, 284:33,311-33,319.
16. Donnellan R., Chetty R. Cyclin D1 and human neoplasia. Mol. Pathol. 1998, 51:1-7.
17. Fu M., Wang C., Li Z., Sakamaki T., Pestell R.G. Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 2004, 145:5439-5447.
18. Garneau N.L., Wilusz J., Wilusz C.J. The highways and byways of mRNA decay. Nat. Rev. Mol. Cell Biol. 2007, 8:113-126.
19. Ginisty H., Sicard H., Roger B., Bouvet P. Structure and functions of nucleolin. J. Cell Sci. 1999, 112(Pt 6):761-772.
20. Gui C.Y., Ngo L., Xu W.S., Richon V.M., Marks P.A. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:1241-1246.
21. Huang C., Li J., Ma W.Y., Dong Z. JNK activation is required for JB6 cell transformation induced by tumor necrosis factor-alpha but not by 12-O-tetradecanoylphorbol-13-acetate. J. Biol. Chem. 1999, 274:29,672-29,676.
22. Jirawatnotai S., Hu Y., Michowski W., Elias J.E., Becks L., Bienvenu F., Zagozdzon A., Goswami T., Wang Y.E., Clark A.B., Kunkel T.A., van Harn T., Xia B., Correll M., Quackenbush J., Livingston D.M., Gygi S.P., Sicinski P. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature 2011, 474:230-234.
23. Kai L., Samuel S.K., Levenson A.S. Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex. Int. J. Cancer 2010, 126:1538-1548.
24. Kakuguchi W., Kitamura T., Kuroshima T., Ishikawa M., Kitagawa Y., Totsuka Y., Shindoh M., Higashino F. HuR knockdown changes the oncogenic potential of oral cancer cells. Mol. Cancer Res. 2010, 8:520-528.
25. Kawamata N., Chen J., Koeffler H.P. Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood 2007, 110:2667-2673.
26. Knudsen K.E., Diehl J.A., Haiman C.A., Knudsen E.S. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 2006, 25:1620-1628.
27. Lal A., Mazan-Mamczarz K., Kawai T., Yang X., Martindale J.L., Gorospe M. Concurrent versus individual binding of HuR and AUF1 to common labile target mRNAs. EMBO J. 2004, 23:3092-3102.
28. Lebwohl D.E., Muise-Helmericks R., Sepp-Lorenzino L., Serve S., Timaul M., Bol R., Borgen P., Rosen N. A truncated cyclin D1 gene encodes a stable mRNA in a human breast cancer cell line. Oncogene 1994, 9:1925-1929.
29. Liang S.B., Furihata M., Takeuchi T., Iwata J., Chen B.K., Sonobe H., Ohtsuki Y. Overexpression of cyclin D1 in nonmelanocytic skin cancer. Virchows Arch. 2000, 436:370-376.
30. Marderosian M., Sharma A., Funk A.P., Vartanian R., Masri J., Jo O.D., Gera J.F. Tristetraprolin regulates Cyclin D1 and c-Myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling. Oncogene 2006, 25:6277-6290.
31. Marks P.A. Discovery and development of SAHA as an anticancer agent. Oncogene 2007, 26:1351-1356.
32. Meijlink F., Curran T., Miller A.D., Verma I.M. Removal of a 67-base-pair sequence in the noncoding region of protooncogene fos converts it to a transforming gene. Proc. Natl. Acad. Sci. U. S. A. 1985, 82:4987-4991.
33. Motokura T., Bloom T., Kim H.G., Juppner H., Ruderman J.V., Kronenberg H.M., Arnold A. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 1991, 350:512-515.
34. Musgrove E.A., Caldon C.E., Barraclough J., Stone A., Sutherland R.L. Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer 2011, 11:558-572.
35. Nguyen-Chi M., Morello D. Aberrant regulation of mRNA 3' untranslated region in cancers and inflammation. Med. Sci. (Paris) 2008, 24:290-296.
36. Ouyang W., Ma Q., Li J., Zhang D., Liu Z.G., Rustgi A.K., Huang C. Cyclin D1 induction through IkappaB kinase beta/nuclear factor-kappaB pathway is responsible for arsenite-induced increased cell cycle G1-S phase transition in human keratinocytes. Cancer Res. 2005, 65:9287-9293.
37. Ouyang W., Li J., Ma Q., Huang C. Essential roles of PI-3K/Akt/IKKbeta/NFkappaB pathway in cyclin D1 induction by arsenite in JB6 Cl41 cells. Carcinogenesis 2006, 27:864-873.
38. Ouyang W., Li J., Zhang D., Jiang B.H., Huang D.C. PI-3K/Akt signal pathway plays a crucial role in arsenite-induced cell proliferation of human keratinocytes through induction of cyclin D1. J. Cell. Biochem. 2007, 101:969-978.
39. Ouyang W., Zhang D., Ma Q., Li J., Huang C. Cyclooxygenase-2 induction by arsenite through the IKKbeta/NFkappaB pathway exerts an antiapoptotic effect in mouse epidermal Cl41 cells. Environ. Health Perspect. 2007, 115:513-518.
40. Ouyang W., Luo W., Zhang D., Jian J., Ma Q., Li J., Shi X., Chen J., Gao J., Huang C. PI-3K/Akt pathway-dependent cyclin D1 expression is responsible for arsenite-induced human keratinocyte transformation. Environ. Health Perspect. 2008, 116:1-6.
41. Resnitzky D., Reed S.I. Different roles for cyclins D1 and E in regulation of the G1-to-S transition. Mol. Cell. Biol. 1995, 15:3463-3469.
42. Richon V.M., Sandhoff T.W., Rifkind R.A., Marks P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:10,014-10,019.
43. Rong R., Montalbano J., Jin W., Zhang J., Garling M., Sheikh M.S., Huang Y. Oncogenic Ras-mediated downregulation of Gadd153/CHOP is required for Ras-induced cellular transformation. Oncogene 2005, 24:4867-4872.
44. Shaulian E., Karin M. AP-1 in cell proliferation and survival. Oncogene 2001, 20:2390-2400.
45. Ungerstedt J.S., Sowa Y., Xu W.S., Shao Y., Dokmanovic M., Perez G., Ngo L., Holmgren A., Jiang X., Marks P.A. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:673-678.
46. Wiestner A., Tehrani M., Chiorazzi M., Wright G., Gibellini F., Nakayama K., Liu H., Rosenwald A., Muller-Hermelink H.K., Ott G., Chan W.C., Greiner T.C., Weisenburger D.D., Vose J., Armitage J.O., Gascoyne R.D., Connors J.M., Campo E., Montserrat E., Bosch F., Smeland E.B., Kvaloy S., Holte H., Delabie J., Fisher R.I., Grogan T.M., Miller T.P., Wilson W.H., Jaffe E.S., Staudt L.M. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood 2007, 109:4599-4606.
47. Witzel I.I., Koh L.F., Perkins N.D. Regulation of cyclin D1 gene expression. Biochem. Soc. Trans. 2010, 38:217-222.
48. Yamaguchi K., Lantowski A., Dannenberg A.J., Subbaramaiah K. Histone deacetylase inhibitors suppress the induction of c-Jun and its target genes including COX-2. J. Biol. Chem. 2005, 280:32,569-32,577.
49. Yamamoto H., Ochiya T., Takeshita F., Toriyama-Baba H., Hirai K., Sasaki H., Sakamoto H., Yoshida T., Saito I., Terada M. Enhanced skin carcinogenesis in cyclin D1-conditional transgenic mice: cyclin D1 alters keratinocyte response to calcium-induced terminal differentiation. Cancer Res. 2002, 62:1641-1647.
50. Zhang D., Li J., Gao J., Huang C. c-Jun/AP-1 pathway-mediated cyclin D1 expression participates in low dose arsenite-induced transformation in mouse epidermal JB6 Cl41 cells. Toxicol. Appl. Pharmacol. 2009, 235:18-24.